E-Mail
IMAGE: After four hours, if the infection is not treated it kills all the cells (line 1); Unformulated tobramycin keeps the cells alive, but it does not eradicate the infection (line. view more
Credit: UniSA
World-first nanotechnology developed by the University of South Australia could change the lives of thousands of people living with cystic fibrosis (CF) as groundbreaking research shows it can improve the effectiveness of the CF antibiotic Tobramycin, increasing its efficacy by up to 100,000-fold.
The new technology uses a biomimetic nanostructured material to augment Tobramycin - the antibiotic prescribed to treat chronic Pseudomonas aeruginosa lung infections in severe cases of CF - eradicating the infection in as little as two doses.